Evidence mapPaperPMID 39680469Full record

ArticleJournal of neurochemistry2025

CXCR2 immunomodulatory therapy protects against microstructural white matter injury and gait abnormalities but does not mitigate deficits of cognition in a preclinical model of cerebral palsy.

Yuma Kitase, Nethra K Madurai, Rachel J Boyd, Gwendolyn Gerner, Adnan Bibic, Andrew S McCallion, Eric M Chin, Shenandoah Robinson, Lauren L Jantzie

Abstract read
In one paragraph

Article in Journal of neurochemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. White matter injury after brain ischemia.Experimental neurology · 2026
    Review
  2. Review
  3. Neural Circuit Mapping and Neurotherapy-Based Strategies.Cellular and molecular neurobiology · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yuma KitaseDivision of Neonatal-Perinatal Medicine, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Nethra K MaduraiDivision of Neonatal-Perinatal Medicine, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Rachel J BoydMcKusick-Nathans Department of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Gwendolyn GernerDepartment of Neuropsychology, Kennedy Krieger Institute, Baltimore, Maryland, USA.
Adnan BibicDivision of MR Research, Department of Radiology and Radiological Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Andrew S McCallionMcKusick-Nathans Department of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Eric M ChinPhelps Center for Cerebral Palsy and Neurodevelopmental Medicine, Department of Neurology and Developmental Medicine, Kennedy Krieger Institute, Baltimore, Maryland, USA.
Shenandoah RobinsonDivision of Neonatal-Perinatal Medicine, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Lauren L JantzieDivision of Neonatal-Perinatal Medicine, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.ORCID https://orcid.org/0000-0002-5410-3553

Funding

Predoctoral Training Program in Human GeneticsT32GM007814 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI VALLE, DAVID · 1985 to 2021
$10.6M
Training for Clinician Scientists in Pediatric Critical Cardiopulmonary DiseaseT32HL125239 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI BEMBEA, MELANIA MARIA, EVERETT, ALLEN D · 2015 to 2024
$3.0M
Placental Mediated Mechanisms of Perinatal Brain InjuryR01HL139492 · NHLBI · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI JANTZIE, LAUREN LEIGH COONEY · 2018 to 2021
$1.6M
Determination of the clinical relevance of Parkinson disease-associated intronic enhancer of the alpha-synuclein gene, in a novel mouse deletion modelR21NS128604 · NINDS · JOHNS HOPKINS UNIVERSITY · PI KO, HANSEOK, MCCALLION, ANDREW S · 2023 to 2024
$450k
CIHR DFD-181599NHLBI NIH HHS R01 HL139492NHLBI NIH HHS R01HL139492NHLBI NIH HHS T32 HL125239NHLBI NIH HHS T32HL125239NIGMS NIH HHS T32 GM007814NIH HHS T32GM007814NINDS NIH HHS R21 NS128604NINDS NIH HHS R21NS128604
6 · The paper itself

Abstract

Minimizing central nervous system (CNS) injury from preterm birth depends upon understanding the critical pathways that underlie essential neurodevelopmental and CNS pathophysiology. Signaling by chemokine (C-X-C motif) ligand 1 (CXCL1) through its cognate receptor, CXCR2 [(C-X-C motif) receptor 2] is essential for neurodevelopment. Increased CXCR2 signaling, however, is implicated in a variety of uterine and neuropathologies, and their role in the CNS injury associated with perinatal brain injury is poorly defined. To evaluate the long-term efficacy of CXCR2 blockade in functional repair of brain injury secondary to chorioamnionitis (CHORIO), we used an established preclinical rat model of cerebral palsy. We tested the hypothesis that transient postnatal CXCR2 antagonism with SB225002 would reduce gait deficits, hypermobility, hyperactivity, and disinhibition concomitant with repair of functional and anatomical white and gray matter injury. CHORIO was induced in pregnant Sprague Dawley rats on embryonic day 18 (E18). SB225002 (3 mg/kg) was administered intraperitoneally from postnatal day 1 (P1)-P5. Rats were aged to adulthood and tested for gait, open-field behavior and cognitive and executive function deficits using a touchscreen cognitive assessment platform. Results show that transient CXCR2 blockade attenuated microstructural white matter injury after CHORIO consistent with improved anatomical connectivity, and mitigated deficits in gait coordination, posture, balance, paw placement, and stepping (p < 0.05). Animals with CHORIO were hyperactive and hypermobile with fMRI deficits in neural circuitry central to cognition. However, CXCR2 antagonism in CHORIO animals did not normalize open-field behavior, neural activity, or cognition on a touchscreen task of discrimination learning (all p > 0.05). Studies in CXCR2 knockout mice confirmed significantly impaired cognitive performance independent of CHORIO. Taken together, transient postnatal blockade of CXCR2 ameliorates aspects of the lasting neural injury after CHORIO including normalizing gait deficits and white matter injury. However, improvement in essential functional and cognitive domains are not achieved limiting the utility of this therapeutic approach for treatment of perinatal brain injury. This study emphasizes the complex, multi-faceted role of chemokines in typical neurodevelopment, circuit formation, neural network function, and injury response.

Indexed as

Cerebral PalsyRats, Sprague-DawleyReceptors, Interleukin-8BWhite MatterAnimalsAnimals, NewbornChorioamnionitisCognitive DysfunctionDisease Models, AnimalFemaleGaitGait Disorders, NeurologicMalePhenylurea CompoundsPregnancyRatsPhenylurea CompoundsReceptors, Interleukin-8BSB 225002chemokinechorioamnionitisconnectivityCXCL1inflammationplacenta

Identifiers

PMID39680469
PMCPMC11879638

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.